Anthrax Bacillus Isolated from WWII-Era Unit 731 Site; Novel 3D Bioprinting Tech Featured in Nature

1. Researchers isolated Bacillus anthracis from the residual soil of Japan's Unit 731 laboratory.

Researchers isolated Bacillus anthracis from the soil at the site of the former Unit 731 laboratory in Japan. This bacterium poses a high risk of pathogenicity and a biological warfare threat. The article presents relevant genomic analyses, highlighting the importance of microbial forensics in investigating biological threats.

2. 3D Printing Technology Innovates Again, Reaching New Heights《Nature》Main Issue, Title: Three Words, Body: Four Figures

University of Melbourne Team Innovates 3D Printing Technology, Using Acoustic Modulation to Rapidly Generate Centimeter-Scale 3D Structures at Gas-Liquid Boundaries; This Technology Utilizes a Wide Range of Practical Materials with High Resolution and Biocompatibility, Offering Significant Value for Fields Such as Tissue Engineering and Organ Manufacturing. The Relevant Achievements Have Been Published in《Nature》。

3. Shanghai's Two Billion-Dollar M&A Restructuring Funds Targeting Chip and Pharmaceutical Industries Arrive

Shanghai Releases Action Plan to Support M&A of Listed Companies, Establishes 10-Billion-Yuan IC and Biomedicine Industry M&A Fund, Aims to Cultivate 10 Globally Competitive Listed Companies by 2027, Achieve 300 Billion Yuan in M&A Transaction Volume, and Enhance Key Industrial Capabilities.

4. How Far Are We from the Popularization of the Male "Cervical Cancer" Vaccine Backed by the Richest Man?

Chinese Billionaire Zhong Shanshan's Subsidiary of Wantai Bio Receives Approval to Conduct Clinical Trials for the Nine-Valent HPV Vaccine's Male Indication. The HPV vaccine can prevent various cancers and infertility risks in men, with a high global infection rate among males. Although the concept and market in China still need development for male vaccination, multiple companies have started R&D, with Merck and Kang Le Wei Shi making progress.

5. Qilu Pharmaceutical Biologics Project Breaks Through Key Industrialization Technologies in Cell Culture

Qilu Pharmaceutical's Biologic Project Breaks Through Cell Culture Technology; Upon Production, It Will Undertake Commercial Production of Multiple Innovative Drugs. The Company Continues to Increase R&D Innovation, with Several Class 1 New Drugs Approved for Marketing, Contributing to the Treatment of Major Diseases.

6. A Rising Star in Medical Technology Emerges in Shanghai: A Shandong-Based Public Company Injects 200 Million Yuan

Shandong Buchang Pharmaceutical Invests 200 Million Yuan; Its Controlling Subsidiary Shanghai Hepu Completes Industrial and Commercial Change Registration, Adjusting Business Scope to Include Technical Services, Sales and Leasing of Class I and II Medical Devices, in Order to Adapt to Market Changes, Optimize Business Structure, and Improve Efficiency.